SAN DIEGO—(BUSINESS WIRE)—Sept. 25, 2007—ACADIA PharmaceuticalsInc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovativetechnology to fuel drug discovery and clinical development of noveltreatments for central nervous system disorders, today announced thatit has been selected to be one of the inaugural companies in the newNASDAQ(R) NeuroInsights(R) Neurotech Index. The index launched todayand is calculated on a price return basis (NASDAQ:NERV) and a totalreturn basis (NASDAQ:NRVX).
The NASDAQ NeuroInsights Neurotech Index is the first indexdesigned to track the performance of leading neurotechnology companieswhich are listed and actively traded on one of the three major U.S.stock exchanges. The NASDAQ NeuroInsights Neurotech Index includescompanies engaged in researching, developing, manufacturing andmarketing pharmaceuticals, biologics, medical devices and diagnosticsfor the brain and nervous system. In addition to meeting minimummarket criteria, the 32 companies included in the index must beidentified by NeuroInsights as significantly involved in theneurotechnology industry, which includes developing treatments anddiagnostics for disorders like Alzheimer's, addiction, anxiety,depression, epilepsy, multiple sclerosis, obesity, pain, Parkinson's,schizophrenia, sensory disorders, sleep disorders, stroke, andtraumatic brain injury.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovativetechnology to fuel drug discovery and clinical development of noveltreatments for central nervous system disorders. ACADIA currently hasfive mid-to-late stage clinical programs as well as a portfolio ofpreclinical and discovery assets directed at diseases with large unmetmedical needs, including schizophrenia, Parkinson's disease psychosis,sleep maintenance insomnia, and neuropathic pain. All of the drugcandidates in ACADIA's product pipeline emanate from discoveries madeusing its proprietary drug discovery platform. ACADIA's corporateheadquarters is located in San Diego, California and it maintainsresearch and development operations in both San Diego and Malmo,Sweden.
About NeuroInsights
NeuroInsights is the world's leading neurotechnology research andadvisory firm. As the neurotechnology market authority, NeuroInsightshelps investors, industry and society understand and profit from therapid growth in drugs, devices and diagnostics for the brain andnervous system. NeuroInsights provides market reports, investmentinformation, industry events and strategic advisory services toventure funds, startups, corporations, governments and financialinstitutions. For more information, visit www.neuroinsights.com.
About NASDAQ
NASDAQ is the largest U.S. equities exchange. With approximately3,200 companies, it lists more companies and, on average, trades moreshares per day than any other U.S. market. It is home to companiesthat are leaders across all areas of business including technology,retail, communications, financial services, transportation, media andbiotechnology. NASDAQ is the primary market for trading NASDAQ-listedstocks as well as a leading liquidity pool for trading NYSE-listedstocks. For more information about NASDAQ, visit the NASDAQ Web siteat www.nasdaq.com or the NASDAQ Newsroom at www.nasdaq.com/newsroom.
Forward-Looking Statements
Statements in this press release that are not strictly historicalin nature are forward-looking statements. These statements include butare not limited to statements related to the progress of ACADIA's drugdiscovery and development programs and the benefits to be derived fromACADIA's drug candidates and preclinical programs. These statementsare only predictions based on current information and expectations andinvolve a number of risks and uncertainties. Actual events or resultsmay differ materially from those projected in any of such statementsdue to various factors, including the risks and uncertainties inherentin drug discovery, development and commercialization. For a discussionof these and other factors, please refer to ACADIA's annual report onForm 10-K for the year ended December 31, 2006 as well as othersubsequent filings with the Securities and Exchange Commission. Youare cautioned not to place undue reliance on these forward-lookingstatements, which speak only as of the date hereof. This caution ismade under the safe harbor provisions of the Private SecuritiesLitigation Reform Act of 1995. All forward-looking statements arequalified in their entirety by this cautionary statement and ACADIAundertakes no obligation to revise or update this press release toreflect events or circumstances after the date hereof.
CONTACT: ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor Relations
Thomas H. Aasen, Vice President andChief Financial Officer
(858) 558-2871
or
NeuroInsights
Casey Lynch
(415) 229-3225
casey@neuroinsights.com
or
NASDAQ
Wayne Lee
(301) 978-4875
Wayne.D.Lee@NASDAQ.com
SOURCE: ACADIA Pharmaceuticals